Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
Choo N, Keerthikumar S, Ramm S, Ashikari D, Teng L, Niranjan B, Hedwards S, Porter LH, Goode DL, Simpson KJ, Taylor RA, Risbridger GP, Lawrence MG.
Choo N, et al. Among authors: niranjan b.
J Pathol. 2024 Jun;263(2):242-256. doi: 10.1002/path.6280. Epub 2024 Apr 5.
J Pathol. 2024.
PMID: 38578195